Mechanisms of action of arsenic trioxide

Cancer Research

Volumn 62, Issue 14, 2002, Pages 3893-3903

  Miller Jr , Wilson H ^a   Schipper, Hyman M ^a   Lee, Janet S ^a   Singer, Jack ^a   Waxman, Samuel ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; HYBRID PROTEIN; RETINOIC ACID RECEPTOR ALPHA;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER MODEL; CANCER REGRESSION; CARCINOGENICITY; CELL DIFFERENTIATION; CELL FUNCTION; CELL GROWTH; CELL LINE; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG RESPONSE; GROWTH INHIBITION; HUMAN; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; ARSENICALS; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; OXIDES;

EID: 0037099645     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (119)

1. Arsenic trioxide treated 72 cases of acute promyelocytic leukemia
2. Ai-Lin 1 treated 32 cases of acute promyelocytic leukemia
3. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients
4. Treatment of de novo and relapsed acute promyelocytic leukemia patients with arsenic trioxide
5. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: Remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients
6. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide
7. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia
8. Clinical trials of arsenic trioxide in hematologic and solid tumors: Overview of the National Cancer Institute Cooperative Research and Development Studies
9. Clinical trials referral resource. Clinical trials with arsenic trioxide
10. More than a coincidence? The arrival of arsenic and the disappearance of plague in early modern Europe
11. Arsenic and old myths
12. Heavy metals and heavy-metal antagonists
13. Molecular aspects of arsenic stress
14. Therapeutic mule: The use of arsenic in the nineteenth century materia medica
15. Arsenic carcinogenesis in animals and in humans: Mechanistic, experimental, and epidemiological evidence
16. Arsenic and cancer
17. Medicinal arsenic and internal malignancies
18. Metal carcinogenesis: Mechanistic implications
19. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor α gene to a novel transcribed locus
20. Molecular analysis of acute promyelocytic leukemia breakpoint cluster region on chromosome 17
21. A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein
22. PML a growth suppressor disrupted in acute promyelocytic leukemia
23. The PML gene encodes a phosphoprotein associated with the nuclear matrix
24. 4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RARα/PML proteins
25. Arsenic trioxide as an inducer of apoptosis and loss of PML/RARα protein in acute promyelocytic leukemia cells
26. Arsenic-induced PML targeting onto nuclear bodies: Implications for the treatment of acute promyelocytic leukemia
27. Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo
28. 3 exerts dose-dependent dual effects on APL cells
29. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia
30. 3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARα and PLZF-RARα oncoproteins
31. Caspases mediate retinoic acid-induced degradation of the acute promyelocytic leukemia PML/RARα fusion protein
32. Constitutive degradation of PML/RARα through the proteasome pathway mediates retinoic acid resistance
33. PML is essential for multiple apoptotic pathways
34. The function of PML in p53-dependent apoptosis
35. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras
36. Human Daxx regulates Fas-induced apoptosis from nuclear PML oncogenic domains (PODs)
37. PIC-1/SUMO-1-modified PML-retinoic acid receptor α mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia
38. 3 induces apoptosis of the human B lymphoma cell line MBC-1
39. Arsenic trioxide induces apoptosis in human gastric cancer cells through up-regulation of p53 and activation of caspase-3
40. Arsenic trioxide and the growth of human T-cell leukemia virus type I infected T-cell lines
41. Arsenite induces p53 accumulation through an ATM-dependent pathway in human fibroblasts
42. Comparative activity of melarsoprol and arsenic trioxide in chronic B-cell leukemia lines
43. Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARα independent manner
44. Arsenic induces apoptosis in B-cell leukaemic cell lines in vitro: Activation of caspases and down-regulation of Bcl-2 protein
45. Arsenic trioxide-mediated growth inhibition in MC/CAR myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis
46. PML induces a novel caspase-independent death process
47. Life, death and nuclear spots
48. The tumor promoter arsenite stimulates AP-1 activity by inhibiting a JNK phosphatase
49. Signal transduction pathways regulated by arsenate and arsenite
50. Activation of the EGF receptor signaling pathway in human airway epithelial cells exposed to metals
51. Activation of PKC is required for arsenite-induced signal transduction
52. Arsenite induces apoptosis of murine T lymphocytes through membrane raft-linked signaling for activation of c-Jun amino-terminal kinase
53. c-src
54. Dithiothreitol enhances arsenic trioxide-induced apoptosis in NB4 cells
55. Tyrosine phosphatases as targets in metal-induced signaling in human airway epithelial cells
56. Inhibition of NF-κB activation by arsenite through reaction with a critical cysteine in the activation loop of IκB kinase
57. Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway
58. Bcl-2 expression causes redistribution of glutathione to the nucleus
59. Proteasome inhibition: A new strategy in cancer treatment
60. Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells
61. Arsenic trioxide and ascorbic acid: Synergy with potential implications for the treatment of acute myeloid leukaemia?
62. Opposite effect of NF-κB and c-Jun N-terminal kinase on p53-independent GADD45 induction by arsenite
63. 1 phase accumulation by arsenic trioxide in an adult T-cell leukemia cell line, MT-1
64. Arsenic trioxide induces apoptosis in neuroblastoma cell lines through the activation of caspase 3 in vitro
65. Arsenic trioxide induces apoptosis of myeloid leukemia cells by activation of caspases
66. Involvement of CD95-independent caspase 8 activation in arsenic trioxide-induced apoptosis
67. Arsenic inhibition of telomerase transcription leads to genetic instability
68. Possible roles of nitric oxide and redox cell signaling in metal-induced toxicity and carcinogenesis: A review
69. Redox signaling and the emerging therapeutic potential of thiol antioxidants
70. Mechanisms of arsenic carcinogenicity: Genetic or epigenetic mechanisms?
71. Arsenic mediates cell proliferation and gene expression in the bladder epithelium: Association with activating protein-I transactivation
72. Arsenite inhibits Ras-dependent activation of ERK but activates ERK in the presence of oncogenic Ras in baboon vascular smooth muscle cells
73. Involvement of reactive oxygen species and caspase 3 activation in arsenite-induced apoptosis
74. The alteration of mitochondria is an early event of arsenic trioxide induced apoptosis in esophageal carcinoma cells
75. Arsenic trioxide, a novel mitochondriotoxic anticancer agent?
76. Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations
77. Arsenic species that cause release of iron from ferritin and generation of activated oxygen
78. Glutathione peroxidase and catalase modulate the genotoxicity of arsenite
79. Arsenic-induced apoptosis in malignant cells in vitro
80. Mechanism of inhibition of trypanothione reductase and glutathione reductase by trivalent organic arsenicals
81. Thomas Comparative inhibition of yeast glutathione reductase by arsenicals and arsenothiols
82. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system
83. Arsenic trioxide and ascorbic acid induced apoptosis in primary myeloma cells from chemoresistant patients
84. Osmotic regulation of the heat shock response in H4IIE rat hepatoma cells
85. Reactive cysteines of the 90-kDa heat shock protein. Hsp90
86. Heat-induced chaperone activity of HSP90
87. Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90
88. Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells
89. Microsomal heme oxygenase. Characterization of the enzyme
90. Rapid induction of heme oxygenase 1 mRNA and protein by hyperthermia in rat brain: Heme oxygenase 2 is not a heat shock protein
91. Induction of heme oxygenase: A general response to oxidant stress in cultured mammalian cells
92. Heme oxygenase-1: Role in brain aging and neurodegeneration
93. Selenium antagonizes the induction of human heme oxygenase by arsenite and cadmium ions
94. Stress-related gene expression in mice treated with inorganic arsenicals
95. Human lymphocyte heme oxygenase 1 as a response biomarker to inorganic arsenic
96. Bilirubin is an antioxidant of possible physiological importance
97. Bilirubin, formed by activation of heme oxygenase-2, protects neurons against oxidative stress injury
98. Differential cytotoxic effects of arsenic on human and animal cells
99. Mitochondrial oxidative stress after carbon monoxide hypoxia in the rat brain
100. Differential effects of the reversible thiol-reactive agents arsenite and methyl methanethiosulfonate on steroid binding by the glucocorticoid receptor
101. Zinc reversibly inhibits steroid binding to murine glucocorticoid receptor
102. Effects of arsenite on estrogen receptor-α expression and activity in MCF-7 breast cancer cells
103. Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis
104. Arsenic trioxide causes selective necrosis in solid murine tumors by vascular shutdown
105. Arsenic targets tubulins to induce apoptosis in myeloid leukemia ceils
106. Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines
107. Inhibition of mitochondrial energy-linked functions by arsenate. Evidence for a nonhydrolytic mode of inhibitor action
108. 3 on gluconeogenesis
109. Newer developments in arsenic toxicity
110. Arsenic toxicity is enzyme specific and its affects on ligation are not caused by the direct inhibition of DNA repair enzymes
111. Mechanism of protein kinase CK2 association with nuclear matrix: Role of disulfide bond formation
112. Arsenite induces DNA-protein crosslinks and cytokeratin expression in the WRL-68 human hepatic cell line
113. BCR-ABL mediates arsenic trioxide-induced apoptosis independently of its aberrant kinase activity
114. enhances selecti ve cytotoxic effects of ST1-571 against Bcr-Abl-positive acute leukemia cells
115. Folic acid protects SWV/Fnn embryo fibroblasts against arsenic toxicity
116. Arsenic trioxide and interferon-α synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells
117. Arsenic-interferon-α-triggered apoptosis in HTLV-I transformed cells is associated with tax down-regulation and reversal of NF-κB activation
118. 3) in the treatment of chronic myelogenous leukemia: In vitro and in vivo studies